Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Debra L Richardson

Showing results (1-10 of 66) with videos related to

Pageof 7
Sort By:
Gynecologic Oncology Reports|April 10, 2023
Ocular toxicity and mitigation strategies for antibody drug conjugates in gynecologic oncologyDebra L Richardson
Seminars in Oncology Nursing|March 17, 2019
New and Novel Therapies for Gynecologic CancersDebra L Richardson
Current Opinion in Obstetrics & Gynecology|October 14, 2022
Is there a role for secondary debulking in ovarian cancer? A review of the current literatureDanielle Krause, Debra L Richardson
Gynecologic Oncology|June 27, 2006
Risk factors for anastomotic leak after recto-sigmoid resection for ovarian cancerDebra L Richardson, Andrea Mariani, William A Cliby
Cancer Treatment Reviews|November 29, 2022
Targeting NaPi2b in ovarian cancerSusana Banerjee, Ronny Drapkin, Debra L Richardson, et al.
Future Oncology (London, England)|September 4, 2019
Olaparib in the treatment of ovarian cancerChristina R Washington, Debra L Richardson, Kathleen N Moore
Hematology/Oncology Clinics of North America|November 5, 2018
Antibody Drug Conjugates in the Treatment of Epithelial Ovarian CancerDebra L Richardson, Shelly M Seward, Kathleen N Moore
Clinical Obstetrics and Gynecology|February 21, 2012
Evolution of the Gynecologic Oncology Group protocols in the treatment of epithelial ovarian cancerLeigh G Seamon, Debra L Richardson, Larry J Copeland
JAMA Oncology|April 20, 2023
Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients With Platinum Resistance: A Narrative ReviewDebra L Richardson, Ramez N Eskander, David M O'Malley
Obstetrics and Gynecology|February 9, 2016
Risk of Occult Uterine Sarcoma in Women Undergoing Hysterectomy for Benign IndicationsKimberly A Kho, Ken Lin, Martin Hechanova, et al.
Pageof 7

Showing results (1-10 of 66) with videos related to

Sort By:
Pageof 7
Gynecologic Oncology Reports|April 10, 2023
Ocular toxicity and mitigation strategies for antibody drug conjugates in gynecologic oncologyDebra L Richardson
Seminars in Oncology Nursing|March 17, 2019
New and Novel Therapies for Gynecologic CancersDebra L Richardson
Current Opinion in Obstetrics & Gynecology|October 14, 2022
Is there a role for secondary debulking in ovarian cancer? A review of the current literatureDanielle Krause, Debra L Richardson
Gynecologic Oncology|June 27, 2006
Risk factors for anastomotic leak after recto-sigmoid resection for ovarian cancerDebra L Richardson, Andrea Mariani, William A Cliby
Cancer Treatment Reviews|November 29, 2022
Targeting NaPi2b in ovarian cancerSusana Banerjee, Ronny Drapkin, Debra L Richardson, et al.
Future Oncology (London, England)|September 4, 2019
Olaparib in the treatment of ovarian cancerChristina R Washington, Debra L Richardson, Kathleen N Moore
Hematology/Oncology Clinics of North America|November 5, 2018
Antibody Drug Conjugates in the Treatment of Epithelial Ovarian CancerDebra L Richardson, Shelly M Seward, Kathleen N Moore
Clinical Obstetrics and Gynecology|February 21, 2012
Evolution of the Gynecologic Oncology Group protocols in the treatment of epithelial ovarian cancerLeigh G Seamon, Debra L Richardson, Larry J Copeland
JAMA Oncology|April 20, 2023
Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients With Platinum Resistance: A Narrative ReviewDebra L Richardson, Ramez N Eskander, David M O'Malley
Obstetrics and Gynecology|February 9, 2016
Risk of Occult Uterine Sarcoma in Women Undergoing Hysterectomy for Benign IndicationsKimberly A Kho, Ken Lin, Martin Hechanova, et al.
Pageof 7